Navigation Links
Effectiveness of progesterone in reducing preterm births may be altered by genetic predisposition

SAN DIEGO, CA, JAN. 30, 2009 New research that may explain why taking progesterone to prevent preterm birth is only effective for some women was unveiled today at the 29th Annual Society for Maternal-Fetal Medicine (SMFM) meeting The Pregnancy Meeting.

The drug, 17 alpha-hydroxyprogesterone caproate (or 17P), a synthetic form of the progesterone hormone naturally produced during pregnancy, has been demonstrated in clinical trials to prevent some recurrent preterm births but not all.

"This study helps strengthen the theory that genetic variation in the human progesterone receptor plays an important role in the effectiveness of 17P," states Tracy Manuck, M.D., study author and SMFM member.

Women who have a spontaneous preterm delivery are at greatly increased risk of preterm delivery in subsequent pregnancies. Preterm birth is a leading cause of infant death in the United States and babies who survive face serious lifelong health problems. More than 543,000 babies are born too soon each year and recent federal statistics show that the nation's preterm birth rate has risen to 12.8 percent -- a 36 percent increase since the early 1980s.

"Dr. Manuck's research gives us a tantalizing clue as to why 17P works for some women, but not for others," said Alan R. Fleischman, M.D., senior vice president and medical director of the March of Dimes. "With further research along these lines, we hope to someday be able to prevent preterm birth from happening in the first place by screening women before they get pregnant, and identifying those whose babies could get a healthy start in life with the help of 17P."

The research, which was sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Network and the University of Utah, assessed whether women with genetic variations known as single nucleotide polymorphisms (SNPs) in the human progesterone receptor gene were more or less likely to respond to 17P for the prevention of recurrent spontaneous preterm birth.

All patients had at least one prior spontaneous preterm birth. The study extracted DNA from the saliva of 389 patients, and then genotyped 20 SNPs in the region of the progesterone receptor gene. Two hundred and fifty-eight (66 percent) of the study participants received 17P and 131 (34 percent) were controls and received a placebo.

Spontaneous preterm birth was less common among women who received 17P. However, after controlling for factors known to be associated with recurrent prematurity, including smoking, number of prior preterm deliveries, and pre-pregnancy body mass index, two SNPs were identified among African-American patients to be predictive of response to progesterone treatment. There was also an interaction between progesterone treatment and genotype of 3 additional polymorphisms for non-African-American women delivering very preterm (less than 32 weeks gestation).

Today's award-winning study, The Relationship Between Polymorphisms in the Human Progesterone Receptor and Clinical Response to 17 Alpha-Hydroxyprogesterone Caproate for the Prevention of Recurrent Spontaneous Preterm Birth, is the sixth study by SMFM members to be honored by the March of Dimes for innovative research focused on preventing premature births. The March of Dimes is conducting a multi-year, multi-million dollar campaign aimed at using research and awareness to reduce the growing rate of premature birth.


Contact: Elizabeth Lynch
March of Dimes Foundation

Related biology news :

1. UC health news: molecular pathway may predict chemotherapy effectiveness
2. Socioeconomic position associated with effectiveness of HIV drugs
3. MIT model could improve some drugs effectiveness
4. Trial seeks genetic fingerprint for predicting drug effectiveness
5. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
6. Poll Shows Strong Doubts About Effectiveness of Federal Employment Verification System
7. New studies on the Mediterranean diet confirm its effectiveness for chronic disease prevention
8. RNA molecules, delivery system improve vaccine responses, effectiveness
9. New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning
10. Research shows cells inactive state is critical for effectiveness of cancer treatment
11. Corazonas Foods and Brandeis University partner to create cholesterol-reducing snacks
Post Your Comments:
(Date:11/18/2015)... November 18, 2015 --> ... a new market report titled  Gesture Recognition Market - ... 2015 - 2021. According to the report, the global gesture recognition ... anticipated to reach US$29.1 bn by 2021, at a ... North America dominated the global gesture ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... Muncie, IN (PRWEB) , ... November 24, 2015 , ... ... its newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to ... in the last few years. Many AMA members have embraced this type of racing ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
Breaking Biology Technology: